MedTrace Logo

CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users

NCT06467604 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2026-04-15

No results posted yet for this study

Summary

This study aims to assess the impact of GLP-1 receptor agonists, semaglutide and tirzepatide, on food cravings and diet quality in individuals with overweight or obesity. Over 24 weeks, up to 150 adult participants will be monitored using questionnaires and dietary records at 0, 12, and 24 weeks to measure changes in diet quality, disordered eating, food cravings, and hunger. This research, conducted with Seen Medical Group at Knownwell Health Clinic, seeks to fill the gap in literature on the dietary quality effects of GLP-1RAs.

Conditions

Interventions

BEHAVIORAL

Surveys

Participants will be provided electronic surveys at 3 timepoints throughout study.

OTHER

Indirect Calorimetry

Participants will receive indirect calorimetry at 3 time points throughout the study.

OTHER

Body composition

Participants will receive body scans using bioelectrical impedence seca mBCA 554 digital body composition analysis scale 3 time points throughout the study.

OTHER

Anthropometrics

Participants will have their Height, weight, waist circumference, and calculated BMI performed at 3 time points throughout the study.

Sponsors & Collaborators

  • Knownwell

    collaborator UNKNOWN

  • University of California, Davis

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2027-03-12
Completion
2027-04-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06467604 on ClinicalTrials.gov